News from BiOptix

Jun 26, 2014, 15:22 ET
Quantitative SPR Screening of Aptamer-Protein Interactions For Pre-Clinical Development using the BiOptix 404pi (PRNewsFoto/BiOptix)
Jun 05, 2014, 11:11 ET
Feb 18, 2014, 14:18 ET
Dec 11, 2013, 15:22 ET
Sep 26, 2013, 09:26 ET
Jul 08, 2013, 13:13 ET
Jun 26, 2013, 17:39 ET
Apr 08, 2013, 12:31 ET
Dec 03, 2012, 12:03 ET
Nov 01, 2012, 11:01 ET
Oct 25, 2012, 10:25 ET
Sep 24, 2012, 09:24 ET
Sep 11, 2012, 09:11 ET
Aug 22, 2012, 08:22 ET
BiOptix Diagnostics Corporation, a privately held firm based in Boulder, Colorado has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR -- Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction -- with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com.  (PRNewsFoto/BiOptix)

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer